News
Updated and committed to information
NEW UPDATE ON GUIDELINES FOR PREDICTIVE BIOMARKERS IN NON-SMALL CELL LUNG CANCER (NSCLCP)
Non-small cell lung cancer (NSCLC) has the largest number of identified therapeutic targets, some of which have therapeutic utility. The use of next-generation sequencing facilitates
BLOOD TEST TO DETECT CANCER BY IDENTIFYING CIRCULATING TUMOR DNA
Researchers at the University of Wisconsin School of Medicine and Public Health (Madison, WI, USA) have developed a blood test that is able to detect
PERIPHERAL BLOOD CYTOGENETIC MONITORING IN AZACITIDINE-TREATED PATIENTS WITH HIGH-RISK MDS
In this single-center retrospective analysis, the response of 76 patients with high-risk myelodysplastic syndrome (MDS) treated with azacitidine (AZA) was reviewed, especially the cytogenetic response
PAM50 GENETIC TEST IDENTIFIES TRIPLE-NEGATIVE BREAST CANCER PATIENTS WHO MAY BENEFIT FROM ADJUVANT CAPECITABINE
Patients with non-basal triple-negative breast cancer are those who benefit most from chemotherapy with oral capecitabine as adjuvant treatment, according to a new analysis of
LUNG CANCER DAY
Immunochemotherapy and the search for biomarkers mark a paradigm shift in lung cancer. The possibilities offered by these treatments in combination with conventional tools, such
CLINICAL EFFICACY OF SEQUENTIAL TREATMENTS IN METASTATIC KRASG12C-MUTATED COLORECTAL CANCER
This multicenter clinical trial evaluated the clinical efficacy of sequential treatments in patients with metastatic colorectal cancer with G12C mutation of the KRAS gene who
